

Australia's IonOpticks ushers in new age of proteomics with launch of Aurora Frontier

25 November 2022 | News

IonOpticks developed Aurora Frontier to meet the demands of customers and mass spectrometry vendors who wanted better separation of samples to unlock the full potential of mass spectrometers

The field of proteomics is set to be revolutionised with the launch of Australia-based IonOpticks' Aurora Frontier that achieves more than 10,000 proteins per sample. This near-full proteome coverage, a depth previously considered unattainable, unlocks the potential for ground-breaking scientific discoveries in human health.

Despite the awareness of the potential of proteomics, advancements in research have been held back by the lack of innovative technology available to drive progress in the field. The capabilities in mass spectrometry have improved significantly over the last decade, however, its true potential is only realised when paired with the best possible chromatographic column.

Aurora Frontier is a 60cm nanoflow UHPLC packed emitter column and boasts class-leading performance using long sample gradients, enabling researchers to get more depth of coverage due to its unmatched peak capacity when compared to other nanoflow chromatography.

Studies show the product can produce more than 10,000 unique protein IDs, over 25 per cent more than the next highest performing commercially available column for single species samples.

IonOpticks' columns are used for a broad range of applications within the field of biological and medical research including infectious diseases, drug discovery, cancer biology and Alzheimer's disease, enabling scientists and clinicians to discover more from their samples and achieve data quality and deep proteome coverage on a whole new scale.

Frontier is part of IonOpticks' Aurora Series and follows the launch of its Generation 3 product base which launched the highest-performing and most user-friendly UHPLC columns available.